Trial Profile
Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Dysmenorrhoea; Endometriosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 02 Sep 2022 Results assessing changes in health-related quality of life of Japanese women, published in the Advances in Therapy.
- 10 Jan 2022 Status changed from active, no longer recruiting to completed.
- 18 Jul 2021 Planned End Date changed from 30 Jun 2021 to 31 Dec 2021.